AbbVie and Eli Lilly are competing in the pharmaceutical market.
7 reports, 6 independent
Updated Oct 9
Gone quiet
- Reports
- 7
- Developments
- 3
- Repetition
- 57%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
AbbVie and Eli Lilly are competing in the pharmaceutical market.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Lilly's Zepbound faces competition from Novo; AbbVie sees gains from recent buyout deals.1 source
AbbVie and Eli Lilly are competing in the specialized pharmaceutical market.1 source
AbbVie and Eli Lilly are competing in the pharmaceutical market.1 source
Keep exploring
Part of
AbbVie and others are managing drug exclusivity, seeking next-gen immunology pipeline growth, and competing for market share.Also in this story
- AbbVie is developing ABBV-466, a potential successor to Skyrizi, whose patents may expire by 2033.
- M&A activity is driving sector recovery.
The entities involved
-
AbbVie
pharmaceutical company
Nothing else this week.
-
Eli Lilly and Company
American pharmaceutical company
Related events
- Major pharmaceutical companies, including Eli Lilly, Johnson & Johnson, and AbbVie, are significant holdings in various health care ETFs.
- Agreement between Eli Lilly and Hims & Hers Health expands access to Lilly's medicines.
- AbbVie products are succeeding Humira in the market, while FDA approvals and Fed caution influence market expectations.
- MarketBeat listed Eli Lilly and Company among stocks to watch on October 31, 2026.
- Eli Lilly, AbbVie, and BridgeBio were recognized as top large employers in recent rankings.